RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report

Patients with metastatic pancreatic cancer have limited treatment options and a dismal prognosis. While RET fusion is rare (0.6%) in pancreatic cancer, the efficacy of RET-targeted treatment in patients with TRIM33-RET fusion has not been previously reported. Herein, we presented a case of a 68-year...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tongyi, Wang, Hongwei, Cai, Zhiwei, Zhang, Siqi, Jiang, Chongyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149926/
https://www.ncbi.nlm.nih.gov/pubmed/37139148
http://dx.doi.org/10.3389/fonc.2023.1078076
_version_ 1785035252169703424
author Zhang, Tongyi
Wang, Hongwei
Cai, Zhiwei
Zhang, Siqi
Jiang, Chongyi
author_facet Zhang, Tongyi
Wang, Hongwei
Cai, Zhiwei
Zhang, Siqi
Jiang, Chongyi
author_sort Zhang, Tongyi
collection PubMed
description Patients with metastatic pancreatic cancer have limited treatment options and a dismal prognosis. While RET fusion is rare (0.6%) in pancreatic cancer, the efficacy of RET-targeted treatment in patients with TRIM33-RET fusion has not been previously reported. Herein, we presented a case of a 68-year-old man with pancreatic cancer harboring TRIM33-RET fusion who responded remarkably to pralsetinib despite being intolerant to chemotherapy. To our knowledge, this is the first report on the clinical value of a single TRIM33-RET fusion in pancreatic cancer, which may benefit from the targeted therapy.
format Online
Article
Text
id pubmed-10149926
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101499262023-05-02 RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report Zhang, Tongyi Wang, Hongwei Cai, Zhiwei Zhang, Siqi Jiang, Chongyi Front Oncol Oncology Patients with metastatic pancreatic cancer have limited treatment options and a dismal prognosis. While RET fusion is rare (0.6%) in pancreatic cancer, the efficacy of RET-targeted treatment in patients with TRIM33-RET fusion has not been previously reported. Herein, we presented a case of a 68-year-old man with pancreatic cancer harboring TRIM33-RET fusion who responded remarkably to pralsetinib despite being intolerant to chemotherapy. To our knowledge, this is the first report on the clinical value of a single TRIM33-RET fusion in pancreatic cancer, which may benefit from the targeted therapy. Frontiers Media S.A. 2023-04-17 /pmc/articles/PMC10149926/ /pubmed/37139148 http://dx.doi.org/10.3389/fonc.2023.1078076 Text en Copyright © 2023 Zhang, Wang, Cai, Zhang and Jiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhang, Tongyi
Wang, Hongwei
Cai, Zhiwei
Zhang, Siqi
Jiang, Chongyi
RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report
title RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report
title_full RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report
title_fullStr RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report
title_full_unstemmed RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report
title_short RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report
title_sort ret rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149926/
https://www.ncbi.nlm.nih.gov/pubmed/37139148
http://dx.doi.org/10.3389/fonc.2023.1078076
work_keys_str_mv AT zhangtongyi retrearrangementpositivepancreaticcancerhasremarkableresponsetopralsetinibacasereport
AT wanghongwei retrearrangementpositivepancreaticcancerhasremarkableresponsetopralsetinibacasereport
AT caizhiwei retrearrangementpositivepancreaticcancerhasremarkableresponsetopralsetinibacasereport
AT zhangsiqi retrearrangementpositivepancreaticcancerhasremarkableresponsetopralsetinibacasereport
AT jiangchongyi retrearrangementpositivepancreaticcancerhasremarkableresponsetopralsetinibacasereport

Ejemplares similares